Rolapitant concentration response in lung cancer and normal epithelial cells
Cell-based study · A549, H1299, H460 and H1975 human lung cancer cells; BEAS-2B normal lung epithelial comparator [1]
After 72 hours, reported CCK-8 IC50 values ranged from 10.70 to 13.90 μM in the four cancer cell lines, compared with 19.69 μM in BEAS-2B. The normal-cell comparator also had a finite IC50; these data do not establish absence of normal-cell toxicity.
| Endpoint | Reported result | Reference |
|---|---|---|
| 72-hour CCK-8 cell viability in A549 | IC50 10.70 μM | [1] |
| 72-hour CCK-8 cell viability in H1299 | IC50 13.90 μM | [1] |
| 72-hour CCK-8 cell viability in H460 | IC50 11.30 μM | [1] |
| 72-hour CCK-8 cell viability in H1975 | IC50 12.05 μM | [1] |
| 72-hour CCK-8 cell viability in BEAS-2B | IC50 19.69 μM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–40 μM rolapitant concentration range, Figure 2A caption
- Exposure duration
- 72 h
- Method
- Cell treatment followed by CCK-8 viability assessment
- Vehicle
- DMSO comparator in shared Cell viability assays method; final DMSO percentage not stated.
- Reported limits
- IC50 confidence intervals and final DMSO percentage are not reported in the adopted locations. Values use the Results text; Figure 2A labels round H1975 and BEAS-2B to 12.1 and 19.7 μM.
Methods and source locations
Compound reported in the paper: Rolapitant; Compound label in the paper: S5476 (Selleck)
Literature findings for the reported rolapitant reagent; no Adooq lot validation or salt conversion.
Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources
72-hour CCK-8 cell viability in A549: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources
72-hour CCK-8 cell viability in H1299: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources
72-hour CCK-8 cell viability in H460: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources
72-hour CCK-8 cell viability in H1975: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources
72-hour CCK-8 cell viability in BEAS-2B: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources